Raymond James Financial Services Advisors
NRXP icon

Raymond James Financial Services Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,157
Closed -$55K – 3422
2021
Q4 		$55K Buy
+1,157
New +$83.5K ﹤0.01% 3174

Other funds holding NRXP

Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial Services Advisors's NRXP Position: Q1 2022 in Review

Raymond James Financial Services Advisors sold out of NRX Pharmaceuticals (NRXP) in Q1 2022, closing a stake of 1,157 shares — an estimated $55K sold.

Raymond James Financial Services Advisors first reported a position in NRXP in Q4 2021 and held it in 1 quarter. The position peaked at $55K in Q4 2021. 34 funds tracked by Wall St. Rank hold NRXP as of Q1 2022.

  • Raymond James Financial Services Advisors reported no remaining NRX Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 1,157 NRX Pharmaceuticals shares in Q1 2022, an estimated $55K.
  • Raymond James Financial Services Advisors first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's NRX Pharmaceuticals position peaked at $55K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2022, filed 11 May 2022.